Merck buys drug companies in Uruguay, Turkey

Prondil S.A. and Vilsan Pharmaceuticals focus on the livestock sector.

Merck buys drug companies in Uruguay, Turkey
Prondil’s Prondiclos P vaccine and Vilsan’s Akarvil antiparasitic.

Merck Animal Health is expanding its international business with the acquisition of South American and Turkish vaccine manufacturers.

Madison, New Jersey-based Merck reported Dec. 6 that it purchased Prondil S.A. of Montevideo, Uruguay. Privately held Prondil develops and manufactures livestock vaccines and antigens for sale in more than 20 countries.

In mid-November, Merck agreed to acquire Vilsan Pharmaceuticals, which makes drugs and vaccines for livestock, poultry and fish. Vilsan, also privately held, is headquartered in Istanbul, Turkey, and operates a factory in Ankara.

The transaction terms were not announced.

Merck Animal Health is striving “to expand our vaccine leadership and add more breadth to our portfolio,” President Rick DeLuca said.

“This acquisition of Prondil provides expertise and biologics manufacturing capacity as well as a complementary portfolio of specialized livestock vaccines,” DeLuca said.

The addition of Vilsan “will bring value and new options to our customers in this growing region,” said Philippe Houffschmitt, general manager of MSD Animal Health Turkey.